|Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2010: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
I have already reported feasibility of gene therapy for gastrointestinal cancer. Furthermore, I made new conditional replicative adenovirus(ADP CRAds) that was enhanced anti tumor effect with mutation and deletion in E3 region. Using this back bone, we success to make CXCR4 ADP Luc CRAds that replication was controlled by CXCR4 promoter. On the other hand, we imaged anti tumor effect using Cox2 ADP Luc CRAds that replication was controlled by Cox2 promoter and compared with existing methods. Cox2 ADP Luc CRAds indicated that its intensity of luminescence was more correlate with pathological anti tumor effect than existing method. Then, our imaging ADP CRAds have a potency to be a new tool for evaluation of anti tumor effect in chemotherapy.